Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

• Status: Completed
• Trial end date: 2004-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Spontaneous intracranial haemorrhage (ICH) within 3 hours after first symptom

Exclusion Criteria:

• Patients with secondary ICH

• Pre-existing disability

• Haemophilia